More Research May Be Needed Into Possible Benefit Of Extending Duration Of Treatment With DAAs For Patients With Detectable HCV RNA At Four Weeks

Infectious Disease Advisor (6/29, Schad) reports on a “retrospective, single-center study” indicating that “further studies are needed to guide clinicians on whether to extend the duration of treatment with direct-acting antivirals (DAAs) in patients with...